Clinical genitourinary cancer最新文献

{"title":"Phenotypic Diversity of Immunosuppressive B Cells Associated in Urothelial Carcinoma of the Bladder","authors":"Karuppasamy David Raja ,&nbsp;Aishwarya Singh ,&nbsp;Shamima Akhtar ,&nbsp;Prabhjot Singh ,&nbsp;Amlesh Seth ,&nbsp;Seema Kaushal ,&nbsp;Alpana Sharma","doi":"10.1016/j.clgc.2025.102351","DOIUrl":"10.1016/j.clgc.2025.102351","url":null,"abstract":"<div><h3>Background</h3><div>Urothelial carcinoma of the bladder presents a complex tumor microenvironment, with tumor-infiltrating B cells (TIL-Bs) playing a significant role in disease progression. Although their presence is acknowledged, the phenotypic diversity of regulatory TIL-Bs in bladder cancer remain underexplored.</div></div><div><h3>Materials and Methods</h3><div>In this study, we evaluated core B cell subsets and their immunosuppressive phenotypes in both peripheral blood (n=40) and bladder tumor tissues (n=40) to evaluate their relationship with disease severity.</div></div><div><h3>Results</h3><div>Our findings revealed that high-grade bladder tumors are enriched with B cells and their subsets, particularly transitional B cells and plasmacytes (plasmablasts and plasma cells). However, total memory B cells were reduced in the tumor microenvironment compared to non-tumor tissues. It was further revealed that the high-grade tumors demonstrated significant infiltration of regulatory B cells (Breg), with elevated levels of IL10+ and TGFβ+ Breg cells as well as IL-10+TGF-β+ dual-cytokine-secreting Breg cells, suggesting their role in fostering an immunosuppressive microenvironment. Memory B cells demonstrated the highest frequency of Breg phenotypes among the B cell subsets. Additionally, Tertiary Lymphoid Structure formation and frequency were associated with disease severity, the differentiated B cells and IL10+ Breg cell counts, emphasizing the importance of these structures in bladder cancer progression and the potential involvement in Breg cells formation.</div></div><div><h3>Conclusion</h3><div>This study demonstrates the enrichment of the bladder cancer tumor microenvironment with diverse B cell subsets, including functional Breg cells, which correlates with disease severity.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 4","pages":"Article 102351"},"PeriodicalIF":2.3,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Outcomes and Safety Profile of Neoadjuvant PD-1 Inhibitors Combined With VEGFR-TKI Versus VEGFR-TKI in Nonmetastatic Renal Cell Carcinoma","authors":"Cheoklong Ng ,&nbsp;Cheng Peng ,&nbsp;Shangqian Wang ,&nbsp;Lei Zheng ,&nbsp;Le Qu ,&nbsp;Pei Dong ,&nbsp;Changwei Ji ,&nbsp;Jun Xiao ,&nbsp;Minfeng Chen ,&nbsp;Zhankui Jia ,&nbsp;Tao Zhang ,&nbsp;Xiaoyi Hu ,&nbsp;Taile Jing ,&nbsp;Wei Xiong ,&nbsp;Jianping Wu ,&nbsp;Xiongjun Ye ,&nbsp;Fan Li ,&nbsp;Qing Yang ,&nbsp;Qi Tang ,&nbsp;Juping Zhao ,&nbsp;Jiwei Huang","doi":"10.1016/j.clgc.2025.102353","DOIUrl":"10.1016/j.clgc.2025.102353","url":null,"abstract":"<div><h3>Objective</h3><div>The effectiveness of combining immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) in neoadjuvant therapy for renal cell carcinoma (RCC) remains unclear. This study aim to compare the efficacy and safety of neoadjuvant ICI plus TKI combination therapy versus TKI monotherapy in locally RCC patients.</div></div><div><h3>Methods</h3><div>This study included 185 cases of locally RCC disease(TanyNanyM0) receiving neoadjuvant therapy from 29 centers across China from January 2019 to Feburary 2024. Primary endpoint was the objective response rate (ORR) in all patients and patients with tumor thrombus (TT). Secondary endpoints included recurrence-free survival (RFS), overall survival (OS), surgical outcomes, and safety. Statistical analysis was performed to compare the results between 2 groups.</div></div><div><h3>Results</h3><div>Combination therapy group had higher ORR compared to the TKI monotherapy group(30.9% vs. 16.3% in all patients, 34.5% vs. 15.6% in patients with TT) and pCR rate (14.8% vs. 0%). RFS rates were improved in patients with TT receiving combination therapy (<em>P</em> = .047). Furthermore, the combination therapy group had lower blood loss during surgery (200 mL vs. 300 mL, <em>P</em> = .004). The main limitation is the retrospective study design.</div></div><div><h3>Conclusions</h3><div>Neoadjuvant ICI plus TKI combination therapy showed promising efficacy and acceptable toxicity. These findings suggest that further investigation is warranted to explore the potential of this treatment approach.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 4","pages":"Article 102353"},"PeriodicalIF":2.3,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144055463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Very Early Relapse (< 1 year) in de novo Metastatic Seminoma is Associated With Reduced Overall Survival","authors":"Pia Paffenholz ,&nbsp;F. Seelemeyer ,&nbsp;Ruben Gößmann ,&nbsp;Melanie von Brandenstein ,&nbsp;David Pfister ,&nbsp;Axel Heidenreich","doi":"10.1016/j.clgc.2025.102347","DOIUrl":"10.1016/j.clgc.2025.102347","url":null,"abstract":"<div><h3>Introduction</h3><div>As the characteristics and outcome associated with relapse in seminomatous testicular germ cell tumors (STGCT) are still unclear, this study aims at evaluating the differences between very early relapse (VER) and later relapse (LR) in this cohort of patients.</div></div><div><h3>Material and methods</h3><div>This retrospective analysis included 459 patients with STGCT treated from 2000 to 2024, analysing patient characteristics with nonparametric statistics as well as follow-up using Kaplan Meier analyses. VER was defined as tumour recurrence &lt; 12 months after successful treatment.</div></div><div><h3>Results and limitations</h3><div>About 94 (20%) patients relapsed during a median follow-up of 19 months [IQR 2-68]. De novo metastatic patients with VER (<em>n</em> = 38, 40%) showed a significantly higher number of clinical stages 2C-3 disease (21% vs. 4%, <em>P</em> = .007), M-stage (<em>P</em> = .009) at diagnosis as well as a higher HCG level (<em>P</em> = .030) and LDH levels (<em>P</em> &lt; .001; &gt;2x ULN <em>P</em> = .039) at start of chemotherapy compared to patients with LR (<em>n</em> = 56; 60%). Initial treatment did not significantly differ between VER and LR (<em>P</em> = .199). VER after initial metastatic disease was associated with a significantly reduced overall survival compared to LR (<em>P</em> = .046), however not after de novo stage I. Our study is limited by its retrospective design.</div></div><div><h3>Conclusion</h3><div>Relapse in seminoma occurred in 20% of all patients. In the initial metastatic stage, VER was associated with a higher metastatic burden at diagnosis compared to LR, leading to a reduced overall survival in VER. Consequently, treating physicians should be aware of these patients portending a worse prognosis, potentially discussing an early intensification of systemic treatment.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 4","pages":"Article 102347"},"PeriodicalIF":2.3,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143922425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the Performance of Systematic Sampling Combined With MRI-TRUS Fusion Biopsy and Concordance After Radical Prostatectomy","authors":"Héctor Ayerra Perez ,&nbsp;Javier Fermin Barba Abad ,&nbsp;Virginia Moreno Nieto ,&nbsp;Josep M. Campa Bortolo ,&nbsp;Egoitz Tolosa Eizaguirre","doi":"10.1016/j.clgc.2025.102361","DOIUrl":"10.1016/j.clgc.2025.102361","url":null,"abstract":"<div><h3>Background</h3><div>MRI-guided prostate biopsy allows the targeted sampling of suspicious lesions. However, limitations of MRI and MRI-TRUS fusion biopsy techniques may lead to an underdiagnosis, and thus, some patients may benefit from combining systematic sampling with targeted sampling during prostate biopsy. We aim to assess the diagnostic yield of systematic sampling on MRI-TRUS fusion biopsy pathological result and the histopathological concordance after radical prostatectomy.</div></div><div><h3>Methods</h3><div>We retrospectively compared the prostate cancer (PCa) and clinically significant prostate cancer (csPCa) detection rate (CDR) during the MRI-TRUS fusion biopsy in the targeted sampling with the combination of targeted and systematic samplings. A subgroups analysis was performed considering the PSA density, PIRADS score and the personal history of previous biopsies. We also evaluated the concordance after radical prostatectomy.</div></div><div><h3>Results</h3><div>188 patients submitted to targeted and systematic sampling during the MRI-TRUS fusion biopsy were included. Overall increases of 5.8% and 2.2% in terms of CDR of PCa and csPCa were observed by adding a systematic sampling over the targeted one. Patients with a PIRADS score 4 to 5, PSA density ≥ 0.15 ng/mL², or a history of biopsy showed a significant increase in CDR. Combining systematic sampling with targeted sampling improved the concordance in ISUP grade by 10% (43.6% vs 33.3%) and the kappa statistic by 0.08 (0.20 vs. 0.12).</div></div><div><h3>Conclusions</h3><div>In our experience, the combination of systematic sampling improves the cancer detection rate, especially in patients with highly suspicious radiological findings or a history of biopsy, and increases the concordance after radical prostatectomy.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 4","pages":"Article 102361"},"PeriodicalIF":2.3,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144070382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Histotripsy in the Management of RCC: A New Frontier in Focused Therapies","authors":"Etan Eigner ,&nbsp;Kamil Malshy ,&nbsp;Jathin Bandari ,&nbsp;Nicola Fazaa ,&nbsp;Ameer Nsair ,&nbsp;Laena Hines ,&nbsp;Melissa Atallah ,&nbsp;Jean V. Joseph ,&nbsp;Phillip M. Rappold","doi":"10.1016/j.clgc.2025.102360","DOIUrl":"10.1016/j.clgc.2025.102360","url":null,"abstract":"<div><div>Histotripsy is a noninvasive, ultrasound-based tissue focused technique that uses focused high-intensity sound waves to mechanically fractionate tissue without causing thermal damage. Initially explored in preclinical studies, histotripsy has shown promising results in various solid tumor models, demonstrating its potential as an effective treatment option for oncological conditions. The technique works by creating microbubbles within the targeted tissue, leading to mechanical disruption and cell death while minimizing harm to surrounding healthy structures. This makes histotripsy particularly advantageous for tumors located near critical anatomical structures or in patients for whom traditional surgical methods are not viable.</div><div>Early <em>in vitro</em> and <em>in vivo</em> studies have reported promising outcomes, including successful tumor reduction and improved survival in animal models. However, the translation of these findings into clinical practice is still in progress. Ongoing clinical trials aim to determine the safety, efficacy, and long-term outcomes of histotripsy in the treatment of primary solid renal tumors. These trials will help define optimal treatment protocols, identify ideal patient populations, and explore potential combinations with other therapies. As clinical evidence continues to emerge, histotripsy is expected to become a valuable noninvasive alternative for treating solid tumors, including RCC. It holds particular promise for patients with tumors in challenging locations or those who are poor candidates for conventional interventions.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 4","pages":"Article 102360"},"PeriodicalIF":2.3,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143935364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Renal Function Eligibility Criteria on Clinical Trials and Real-World Survival Outcomes Among Patients With Metastatic Renal Cell Carcinoma","authors":"Xiaoliang Wang ,&nbsp;Jill Hasler ,&nbsp;Benjamin Miron ,&nbsp;Mengru Wang ,&nbsp;Anosheh Afghahi ,&nbsp;Trevor J. Royce ,&nbsp;Daniel M. Geynisman","doi":"10.1016/j.clgc.2025.102362","DOIUrl":"10.1016/j.clgc.2025.102362","url":null,"abstract":"<div><h3>Background</h3><div>Registration trials of first-line (1L) therapies in metastatic renal cell carcinoma (mRCC) employed strict renal function criteria, which may not reflect real-world patients. We evaluated the impact of trial-based renal function eligibility criteria on real-world outcomes.</div></div><div><h3>Methods</h3><div>Using a nationwide, deidentified electronic health record-derived database, we included patients diagnosed with mRCC between January 2011 and April 2023 who received 1L systemic therapy. Renal function criteria were based on trial protocols and included serum creatinine (≤1.5 vs &gt;1.5 x upper limit of normal), estimated glomerular filtration rate (≥30 vs &lt;30 mL/min/1.73 m²), and calculated creatinine clearance (≥40 vs &lt;40 mL/min). Outcomes were real-world progression-free survival (rwPFS) and overall survival (rwOS) from 1L. Statistical analyses included inverse probability of treatment weighted Kaplan-Meier methods and Cox proportional hazard models with multiple imputation.</div></div><div><h3>Results</h3><div>Among 6896 patients, 4647 (67.4%) met all renal function criteria (<em>Included</em>), 586 (8.5%) met at least one (<em>Relaxed</em>), 174 (2.5%) met none (<em>Excluded</em>), and 1489 (21.6%) had unknown renal function (<em>Unknown</em>). In adjusted analyses, patients in the Relaxed and Excluded groups combined had a lower median rwPFS (hazard ratio [HR], 1.12; 95% CI, 1.00-1.25) and rwOS (HR, 1.23, 95% CI, 1.08-1.39) than those in the Included group.</div></div><div><h3>Conclusion</h3><div>Patients who met all renal function criteria had better survival outcomes than those who did not, suggesting that clinical trial results for mRCC may not be fully generalizable to real-world patients.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 4","pages":"Article 102362"},"PeriodicalIF":2.3,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting KIT With Antibody-Drug Conjugates in Chromophobe Renal Cell Carcinoma","authors":"Michel Alchoueiry ,&nbsp;Hadi Mansour ,&nbsp;Damir Khabibullin ,&nbsp;Tiegang Han ,&nbsp;Saireudee Chaturantabut ,&nbsp;Wafaa Bzeih ,&nbsp;Yan Tang ,&nbsp;Jessica F. Williams ,&nbsp;Michelle S. Hirsch ,&nbsp;Carmen Priolo ,&nbsp;William R. Sellers ,&nbsp;Elizabeth P. Henske","doi":"10.1016/j.clgc.2025.102359","DOIUrl":"10.1016/j.clgc.2025.102359","url":null,"abstract":"<div><h3>Introduction</h3><div>Chromophobe renal cell carcinoma (ChRCC) is the third most common type of RCC. There are no proven therapies for patients with metastatic ChRCC, with a median survival of 27 months. KIT (CD117) is a membrane-associated tyrosine kinase receptor. Antibody-drug conjugates (ADC) targeting KIT were previously found to be safe and effective in preclinical models of KIT-positive cancers but have not been tested in ChRCC.</div></div><div><h3>Results</h3><div>In The Cancer Genome Atlas, KIT mRNA expression is higher in ChRCC than any other tumor type with the mean expression 12 times higher than matched normal kidney. Of the 15 metastatic ChRCC specimens stained for KIT at our institution, 87% were positive. In single-cell RNA sequencing data, KIT and SCF, the KIT ligand, are co-expressed in ChRCC tumor cells.</div><div>We found that KIT mRNA expression is significantly higher in ChRCC-derived cells compared to clear cell renal cell carcinoma (ccRCC)-derived cells and normal kidney cells. Western blot analysis confirmed KIT expression in 5 ChRCC cell lines. Despite high KIT expression, knockdown of KIT or treatment with KIT targeting tyrosine kinase inhibitors did not decrease ChRCC cell proliferation.</div><div>LOP628, a KIT ADC, decreased the viability of the ChRCC-derived cells by ∼60% with no effect on ccRCC cells.</div></div><div><h3>Conclusion</h3><div>Together, these data demonstrate that KIT is a viable therapeutic target for antibody-drug conjugates in ChRCC, providing a foundation for further investigation into KIT-targeted therapies.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 4","pages":"Article 102359"},"PeriodicalIF":2.3,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144105637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Creatinine-Cystatin C Ratio as a Promising Prognostic Biomarker in Patients With UTUC After Radical Nephroureterectomy","authors":"Lei Zheng ,&nbsp;Jianjun Ye ,&nbsp;Qihao Wang ,&nbsp;Qiyou Wu ,&nbsp;Kai Chen ,&nbsp;Qiang Wei ,&nbsp;Yige Bao","doi":"10.1016/j.clgc.2025.102352","DOIUrl":"10.1016/j.clgc.2025.102352","url":null,"abstract":"<div><h3>Purpose</h3><div>The aim of this study was to determine the impact of the preoperative creatinine-cystatin C ratio (CCR) on the survival prognosis of patients following radical nephrectomy (RNU) for upper tract urothelial carcinoma (UTUC).</div></div><div><h3>Methods</h3><div>The retrospective analysis was conducted on UTUC patients who underwent radical nephrectomy (RNU) at West China Hospital between January 2009 and December 2019. The endpoint of the study was cancer-specific survival (CSS). Kaplan-Meier curves were used to estimate survival, and Cox proportional hazards modelling was used to assess risk. Nomograms were developed to predict CSS at 3 and 5 years of age, and the predictive power was assessed.</div></div><div><h3>Results</h3><div>A critical CCR of 59.61 µmol/mg was demonstrated to affect 504 patients with UTUC who had undergone RNU. A correlation was identified between a lower preoperative CCR and a considerably worse CSS. In patients with UTUC, CCR was identified as an independent risk factor for CSS, particularly in patients with locally advanced UTUC (pT ≥ 3) (HR: 1.84, 95% CI: 1.14, 2.97). Moreover, the CCR-based nomogram exhibited robust predictive capacity, with areas under the curve for the 3- and 5-year CSS reaching 0.823 and 0.793, respectively.</div></div><div><h3>Conclusion</h3><div>Preoperative CCR is an independent predictor of CSS in UTUC patients receiving RNU treatment. As such, it should be viewed as a potentially useful customized tool in therapeutic decision-making.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 4","pages":"Article 102352"},"PeriodicalIF":2.3,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144082778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid Modulation of Circulating Adipokines and Inflammatory Cytokines in Localized Prostate Cancer Following Short-Term Leuprolide Therapy","authors":"Adithya K. Yadalam ,&nbsp;Kiranj Chaudagar ,&nbsp;Hope Mumme ,&nbsp;Manoj Bhasin ,&nbsp;Ganesh R. Talekar ,&nbsp;Edmund K. Waller ,&nbsp;Gregory B. Lesinski ,&nbsp;Sagar A. Patel ,&nbsp;Anant Mandawat","doi":"10.1016/j.clgc.2025.102358","DOIUrl":"10.1016/j.clgc.2025.102358","url":null,"abstract":"<div><div><ul><li><span>•</span><span><div>Cardiovascular disease is a leading cause of death in men with localized prostate cancer, and treatment with androgen deprivation therapy (ADT) is known to exacerbate cardiovascular risk; however, the underlying mechanisms driving ADT-associated cardiotoxicity remain unclear.</div></span></li><li><span>•</span><span><div>In this case series, we observed significant alterations in circulating adipocytokine levels following 6 months of therapy with the gonadotropin-releasing hormone agonist, leuprolide, in 10 men with localized prostate cancer.</div></span></li><li><span>•</span><span><div>The significantly elevated adipocytokine levels following treatment with leuprolide highlight the potential role of ADT-induced systemic inflammation and metabolic dysregulation in the leptin (adipose)-osteopontin (bone) axis in men with localized prostate cancer treated with ADT.</div></span></li></ul></div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 4","pages":"Article 102358"},"PeriodicalIF":2.3,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143917801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of the Impact of Grade Heterogeneity on Survival in Ta and T1 Tumors: A Subgroup Analysis of NMIBC Cohort","authors":"Murat Can Karaburun ,&nbsp;Ezgi Dicle Serbes ,&nbsp;Çağrı Akpınar ,&nbsp;Khaled Obaid ,&nbsp;Cagatay Göğüş ,&nbsp;Saba Kiremitci ,&nbsp;Duygu Enneli ,&nbsp;Sümer Baltacı ,&nbsp;Evren Süer","doi":"10.1016/j.clgc.2025.102357","DOIUrl":"10.1016/j.clgc.2025.102357","url":null,"abstract":"<div><h3>Introduction</h3><div>We aimed to compare the RFS and PFS of Ta-MG, Ta-HG, T1-MG and T1-HG groups with the hypothesis that MG tumors may have a better prognosis than pure HG tumors.</div></div><div><h3>Material and Methods</h3><div>Patients with HG-NMIBC in the first TUR specimen between 2010 and 2020 were screened. The first TUR specimens were re-evaluated by experienced uropathologists and the percentage of LG tumor areas accompanying HG areas was determined for each case. HG tumors with accompanying LG rates ranging from 1% to 95% were evaluated as “Mixed-Grade (MG),” while tumors without any LG component (0%) were evaluated as “pure High-Grade (HG).” Survival analysis was performed using the Kaplan-Meier method. RFS and PFS were compared via the log-rank test.</div></div><div><h3>Results</h3><div>Of the 201 patients included in the study, 25 (12.4%) had Ta-MG, 45 (22.4%) had Ta-HG, 43 (21.4%) had T1-MG and 88 (43.8%) had T1-HG tumors. The median follow-up period of the patients was 36 months. The median number of BCG instillations received by the patients was 12 and a total of 102 patients (50.7%) received a minimum of 12 doses of BCG treatment. Recurrence was observed in 6 (24%), 11 (24.4%), 13 (30.2%) and 30 (34.1%) patients in the Ta-MG, Ta-HG, T1-MG and T1-HG groups, respectively. The 36-month RFS rates were 76% (CI: 59-93), 76% (CI: 63-88), 70% (CI: 56-84) and 66% (CI: 56-76), respectively (Log-Rank; <em>P</em> = .701). Progression was observed in 2 (8%), 3 (6.6%), 2 (4.6%) and 19 (21.6%) patients, respectively. The 36-month PFS rates for groups were 92% (CI: 82-100), 93% (CI: 86-100), 95% (CI: 89-100) and 78% (CI: 70-87), respectively. The T1-HG group was found to have a statistically significantly lower PFS (Log-Rank; <em>P</em> = .016).</div></div><div><h3>Conclusion</h3><div>In BCG-treated NMIBC patients, those with T1-pure-HG tumors have worse PFS compared to those with T1-MG, Ta-HG, and Ta-MG tumors. The presence of pure-HG tumors may hold prognostic importance for NMIBC patients and might be crucial for patient classification and treatment options.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 4","pages":"Article 102357"},"PeriodicalIF":2.3,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143928209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}